Spontaneous intracranial hemorrhage (ICH) represents a common complication in patients with brain metastases and, above all, patients who are on anticoagulation because of cardiovascular complications have a 15% incidence of ICH. Hamulyák and colleagues present results of the Anticoagulation in Brain Cancer (ABC) study, aimed to compare rates of ICH among patients with brain metastases treated with oral anticoagulants or low-molecular-weight heparin and evaluate outcomes. The study found no significant difference in ICH risk between the two anticoagulation groups, even after adjusting for confounders.

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly identified monogenic disorder. Zhao and colleagues present the case of a VEXAS patient achieving prolonged remission with azacitidine. Given the lack of established treatment guidelines for VEXAS syndrome, further research is needed to determine whether to prioritize treatment on controlling the cytokine storm (steroids, JAK inhibitors, or anti-interleukin agents) or on targeting the mutated clone (azacitidine or even in some cases allogeneic hematopoietic stem cell transplantation) and to determine the optimal scheduling for these approaches.